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We analysed the decisions of major European public funding organisations to 
fund or not to fund synthetic biology (SB) and related ethical, legal and social 
implication (ELSI) studies. We investigated the reaction of public organisa-
tions in six countries (Austria, France, Germany, the Netherlands, Switzerland 
and the UK) towards SB that may influence SB’s further development in 
Europe. We examined R&D and ELSI communities and their particular fund-
ing situation. Our results show that the funding situation for SB varies consid-
erably among the analysed countries, with the UK as the only country with an 
established funding scheme for R&D and ELSI that successfully integrates 
these research communities. Elsewhere, we determined a general lack of fund-
ing (France), difficulties in funding ELSI work (Switzerland), lack of an R&D 
community (Austria), too small ELSI communities (France, Switzerland, 
Netherlands), or difficulties in linking existing communities with available 
funding sources (Germany), partly due to an unclear SB definition.
Keywords:  ELSI, public funding, science funding, science policy, 
synthetic biology
1. Introduction
In 2005 the European Commission (EC) convened a high-level expert group to discuss and 
define a new science and technology field termed synthetic biology (SB). The group agreed 
that “Synthetic biology is the engineering of biology: the synthesis of complex, biologically 
based (or inspired) systems which display functions that do not exist in nature” and concluded 
that “This engineering perspective may be applied at all levels of the hierarchy of biological 
structures – from individual molecules to whole cells, tissues and organisms. In essence, 
synthetic biology will enable the design of ‘biological systems’ in a rational and systematic 
way” (EC, 2005). This forward-looking and promising expert statement was in line with 
the EC pathfinder initiative in the 6th framework programme (FP6) called NEST:   
New and Emerging Technologies.
1 NEST came up with calls for synthetic biology-related 
proposals (both science and supporting activities) and ultimately funded 18 synthetic biology 
projects in Europe, with a total budget of over €32 million (Table 1) (EC, 2007). Although 
the EC is funding four new synthetic biology-related projects in FP7 (two in science and two 
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in humanities) it has so far refrained from providing strong support such as in FP6-NEST.   
The main reason for that was that with the end of FP6 and the onset of FP7, the EC decided 
to discontinue the NEST funding programme. According to information from the EC,   
however, the NEST programme was meant to stimulate a research community in Europe, 
with the aim that national funding agencies should later continue to fund scientific projects 
in that area.
Aim of the study
Our study was designed to determine whether the European national funding agencies have, 
since the end of the NEST programme, actually taken up synthetic biology in their   
portfolio as was envisaged by the EC. The aim was to identify the funding situation and the 
development strategies for synthetic biology in Europe based on several representative 
European countries. We wanted to know how European funding agencies define and   
understand synthetic biology, whether they provide specific resources for its research, 
whether interdisciplinary projects can be funded and whether ethical, legal and societal 
issues (ELSI) are taken into account when providing funding support. Our results shed light 
on whether and how synthetic biology has been received and interpreted by major European 
funding agencies and how their support could shape the future of synthetic biology in 
Europe.
2. Methodology
A survey study with interviews with representatives of different public funding organisations 
from six European countries was conducted from September to October 2009. The structure 
Table 1. All synthetic biology projects and their funding that were supported by the European Commission’s 6th 
framework programme NEST
Project acronym Total project cost (in €1000) EC contribution (in €1000)
BIOMODULAR H2 2482 1998
BIONANO-SWITCH 2680 1992
CELLCOMPUT 1716 1716
COBIOS* 2582 2064
EMERGENCE* 1520 1520
EUROBIOSYN 2742 1260
FuSyMEM 1400 1400
HIBLIB 3585 1999
NANOMOT 2400 2250
NEONUCLEI 2464 1949
NETSENSOR 1989 1320
ORTHOSOME 1587  982
PROBACTYS 2541 1900
SYNBIOCOM*  264  264
SYNBIOLOY*  226  226
SYNBIOSAFE*  245  236
SYNTHCELLS 1804 1420
TESSY*  232  232
Total 32459 24728
* Projects that are partly or fully dedicated to societal aspects, technology assessment, education or community 
building.
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of the questionnaire was based on a previous study on bioethics in synthetic biology 
(Ganguli-Mitra et al., 2009). Our intention was to obtain information from enough European 
countries to cover over 60% of the synthetic biology-related research and ELSI research in 
Europe – in relation to the number of publications (using GoPubMed
2) and number of   
(self-selected) scientists (Figures 1 and 2).
Another requirement was that the selected countries also be represented in the   
pan-European ESF (European Science Foundation) known as EUROSYNBIO, which was 
supported by 11 European countries plus Turkey.
3 We finally chose Germany, the United 
Kingdom, France (which did not support the ESF call), Switzerland for their important role 
in European synthetic biology research, and the Netherlands and Austria for their contribution 
to synthetic biology-related ELSI research. We scheduled 11 interviews with representatives 
of the national funding agencies of the six selected countries (by phone, approximately 30 
minutes per interview). The interviews were conducted with the persons in charge of biotech-
nology and/or genome science funding at the:
• 	German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)
• 	Federal Ministry for Education and Research (Bundesministerium für Bildung und 
Forschung, BMBF)
• 	Biotechnological and Biological Sciences Research Council (BBSRC)
• 	Engineering and Physical Sciences Research Council (EPSRC)
• 	National Center for Scientific Research (Centre National de la Recherche Scientifique, 
CNRS)
• 	French National Research Agency (L’Agence nationale de la recherché, ANR)
• 	SystemsX.ch (launched as the Swiss Initiative in Systems Biology)
• 	Austrian Research Promotion Agency’s (FFG) GEN-AU ELSI programme
• 	Austrian Science Fund (FWF)
• 	Netherlands Organisation for Scientific Research (NWO)
• 	Dutch Technology Foundation STW.
Figure 1. Number of synthetic biology-related PubMed publications (up to November 2009).
Search results from GoPubMed using the search terms: “synthetic biology” OR “biological circuit” OR “artificial 
cell” OR “minimal genome” OR “artificial system” OR “artificial ecosystem” OR “XNA” (xeno nucleic acids).   
With these keywords, the US is the world’s leader in publications on synthetic biology, followed by Europe (EU27). 
The six countries selected in our study altogether account for 70.9% of all EU27 publications in synthetic biology.
Source: GoPubMed, data until 3 November 2009.
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Although our interview partners play a key role in the funding agencies, it was   
made clear that their view does not necessarily represent the official point of view of their 
organisation. We promised anonymity to the interview partners for later publications, thus we 
did not add names or positions to the selected quotations in this article.
In addition we searched for online background information about the activities of the 
funding agencies. Nonetheless, our results are predominantly based on the interviews.
3. Results
The results of our work are presented in the following paragraphs, country by country, in 
order to demonstrate the bandwidth in funding activities. The differences in definitions of 
synthetic biology are compiled in Table 2. All interviewees associated synthetic biology with 
biocircuits and metabolic engineering, as well as with an enlarged genetic alphabet and DNA 
with a chemically different backbone. For other subfields such as “creation of life” and 
“minimal genome,” less agreement was found.
Figure 2.  Number of identified scientists working on synthetic biology.
A total of 588 European scientists working in synthetic biology-related areas were contacted to participate in a   
survey on synthetic biology, carried out by the TESSY project. Of the 211 who responded, 130 (or 61.6%) were from 
the UK, Germany, France, Switzerland, Austria or the Netherlands.
Source: Gaisser et al 2009
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National funding organisations
Germany
In Germany, two major national funding organisations account for most of the public   
funding in emerging fields of life sciences. The German Research Foundation (Deutsche 
Forschungsgemeinschaft, DFG) promotes research at universities and other publicly financed 
research institutions in Germany in all branches of science and the humanities by a bottom-up 
approach (responsive-mode). In turn, the Federal Ministry for Education and Research 
(Bundesministerium für Bildung und Forschung, BMBF) adopts a more applied research 
funding strategy. Both the DFG and the BMBF are already actively involved in consider-
ations fostering synthetic biology. Other German funding organisations such as the Volkswagen 
Foundation, the German National Environment Foundation (Deutsche Bundesstiftung 
Umwelt, DBU) and the Bertelsmann Foundation have not yet entered the field of synthetic 
biology.
The DFG co-organised an expert consultation, implying the need for a clear discussion 
and clarification of ethical issues associated with the subtopic “creating artificial life.” 
Therefore, the DFG and BMBF support scientific research projects on the ethical, legal and 
economic aspects of health research and bioscientific research. 
4
Up to January 2010, the DFG has not funded any project with synthetic biology in the 
title. A number of projects, however, have a potential linkage to synthetic biology. 
Additionally, the DFG funds the cluster of excellence “Centre for Biological Signalling 
Studies” (bioss) at the University of Freiburg with €32.5 million for 5 years (2007–2011/12). 
Approximately one fifth of the bioss activities in Freiburg are linked to synthetic biology. 
Additionally, the DFG funds one Emmy-Noether-Scholar in the field of SB (expansion of the 
genetic code). As outlined above, the DFG funds research via a bottom-up approach, i.e. “any 
research idea can be submitted and will be evaluated according to its scientific quality.   
Table 2. Definitions of synthetic biology by interviewed funding representatives
AT-1 AT-2 CH-1 DE-1 DE-2 FR-1 FR-2 NL-1 NL-2 UK-1 UK-2
Biocircuits using standard  
biological parts
+ + + + + + + + ? + +
Biocircuits without standard   
biological parts?
+ + + + + + + + ? + +
Engineering cells to produce  
fine chemicals
+ - + + + + + + + + +
Creating artificial life - + + - - + + - ? + +
Computer software for  
biocircuit design
- + + + + + + + - + -
Artificial ecosystems - - + ? ? + + - - + -
Enlarged genetic alphabet + + + + + + + + + + +
DNA with chemically  
different backbone
+ + + + + + + + + + +
Minimal genome - - + + + + + + ? + +
Understanding the  
origin of life
+ - - + + + + - + + +
Several subfields of synthetic biology were presented to interviewees: “+” means that it was accepted as part of 
synthetic biology, “–” means that it was not, “?” means don’t know. AT-1: first interviewee Austria, AT-2: second 
interviewee Austria, CH: Switzerland, DE: Germany, FR: France; NL: Netherlands; UK: United Kingdom. Areas 
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Thus, the DFG has an efficient means to fund new ideas such as synthetic biology if they are 
of excellent scientific quality” as summarised by a DFG expert who was involved in the 
development of the DFG strategy in the field of synthetic biology.
So far the BMBF has not funded projects with a direct link to synthetic biology, but there 
is a strong interest in this field on the part of the BMBF. In the past the BMBF has taken the 
risk involved in funding emerging sciences and technologies, such as systems biology.   
This field would probably enjoy similar support if the scientific community were to agree on 
the direction of synthetic biology.
On the level of federal states, the German state of Hessen recently announced a €21   
million funding for the synthetic microbiology research cluster “SYNMIKRO” between the 
University of Marburg and the Max Planck Institute for terrestrial microbiology. SYNMIKRO 
receives the highest research funding ever granted by Hessen.
5
In the view of German funders, the synthetic biology community is still small. One inter-
viewee argued “for the size of the synthetic biology community and the number of projects 
in this field, the money currently available is appropriate, though the sum is small.” However, 
the expert observed a continuous growth of the synthetic biology community during the last 
3 years. “If this growth continues there may be the risk of funding shortfall in the future,” 
noted the interviewee.
As outlined by the DFG, there is no restriction in specific topics for research funding. 
Accordingly, funding depends upon scientific quality rather than specific predefined topics, 
and a plethora of different topics could be submitted and will be funded if they convince the 
reviewers. The BMBF sees a clear need for accompanying measures in the field of ELSI and 
outlined that the policy task – as envisaged under the BMBF biotechnology programme – is 
to combine innovations with social responsibility.
6
United Kingdom
In the United Kingdom, national research funding is organised in seven Research Councils 
that work together as Research Councils UK (RCUK). Funding activities in synthetic biology 
are undertaken mainly through the Biotechnological and Biological Sciences Research 
Council (BBSRC) and the Engineering and Physical Sciences Research Council (EPSRC). 
“BBSRC and EPSRC support synthetic biology through individual responsive mode grants 
and core-related research in areas such as systems biology, bioengineering and bionanotech-
nology” as outlined by one interviewee.
Additionally, four UK Research Councils (BBSRC, EPSRC, ESRC and AHRC) have 
come together to fund seven research community networks in synthetic biology led by UK 
universities with a total of nearly €1 million (= £0.9 million). BBSRC currently spends 
around €20.8 million (= £19 million)
7 a year on projects in synthetic biology and core-related 
research areas. EPSRC spent approximately €3.2 million for sign-post activities, e.g. in syn-
thetic biology.
8 In spring 2009, EPSRC and the US National Science Foundation (NSF) 
invited submissions on expressions of interest on a joint call on “New Directions in Synthetic 
Biology Details” and subsequently allocated about €6 million (= £5.5 million) for five 
research projects.
9 Finally, EPSRC is funding the Centre for Synthetic Biology and Innovation 
at Imperial College, London, with €5.3 million (= £4.8 million) between 2009 and 2014. The 
Medical Research Council (MRC) provided over €1.8 million (= £1.6 million) for research 
on synthetic biology in 2007/08. The interviewee of MRC mentioned that “they would also 
consider funding synthetic biology via response-mode [bottom-up approach] but so far MRC 
did not receive many applications in this scientific area.”
Against the background of a broad awareness of synthetic biology in the UK Research 
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Society
10 and the Wellcome Trust,
11 it can be concluded that the funding situation in the UK 
is good. Synthetic biology is among the topics that should be fostered according to BBSRC’s 
strategic plan 2010–2015.
12 By means of different types of measure, this approach addresses 
the full range of levels from research funding, community building, networking and educa-
tion to public dialogue. A report on a public dialogue process regarding synthetic biology was 
recently published by BBSRC and EPSRC (Bhattachary et al., 2010). The dialogue was 
intended to help frame the issues and promote a broader debate on SB. Still, BBSRC and 
EPSRC emphasise the need for the analysis of ELSI in parallel to scientific research and 
development in synthetic biology. For example, EPSRC encouraged, in its latest call on syn-
thetic biology, investigation of ethics and societal issues concurrently with scientific research. 
Additionally, BBSRC’s Bioscience for Society Strategy Panel has considered the ethical, 
legal and societal issues raised by synthetic biology by establishing a Working Group to 
identify key factors relevant to effecting constructive public engagement. BBSRC has also 
commissioned an independent review of the UK’s position in synthetic biology and of the key 
societal issues raised by new research capabilities.
13
France
The French National Research Agency (L’Agence nationale de la recherché, ANR) and the 
National Centre for Scientific Research (Centre National de la Recherche Scientifique, 
CNRS) are the two most important organisations active in promoting the life sciences in 
France. Theoretically, synthetic biology could be funded with the Call for Proposal (CFP) for 
green and white chemistry, complex systems, and within the non-thematic calls. No dedicated 
CFP for synthetic biology has been issued by ANR. Research proposals on synthetic biology 
could be submitted through CFP from the Blanc programme for all research fields, the 
National Bioenergies Research Programme for second- and third-generation biofuels, and the 
Emerging Scientific Challenges and “Memory” Key Project for new needs from emerging 
fields, which includes synthetic biology. So far, one publication on synthetic biology has been 
produced that was supported by the Blanc programme (Mingardon et al., 2007) and several 
ongoing projects are also supported by this programme.
14 As with the situation of ANR, no 
dedicated scheme for synthetic biology has been defined by CNRS. Synthetic biology-related 
projects are funded by CNRS through an interdisciplinary programme of research. Compared 
to its annual budget of €3.36 billion for fiscal year 2009,
15 the budget for a project funded by 
the interdisciplinary programme of CNRS is extremely small: only €50,000 over a period of 
1 year. To date, only two synthetic biology projects have been funded through this pro-
gramme. This indicates that synthetic biology was not on the priority list set by the scientific 
committee from both institutes. Owing to lack of sufficient funding for research in general, 
research priorities are set to support a limited number of projects mainly from already estab-
lished disciplines. A small number of synthetic biology-related research activities in France 
were funded through other French agencies, such as Genopole and the inter-EPST
16 
Bioinformatique (Remy et al., 2003; Yartseva et al., 2007).
With limitations in national funding, French scientists tend to get most of their support 
from pan-European programmes such as the European Research Council (ERC) and the 
European Commission (EC), for projects like PROBACTYS (NEST pathfinder), COBIOS 
and TARPOL.
17 ANR has participated in various European-coordinated activities. It has been 
a partner in several ERA-NETs and a member of the European Science Foundation (ESF) 
although it did not support the ESF EUROSYNBIO call. ANR recognises that scientific 
progress on SB will not be welcomed by the public without addressing its effects on ELSI, 
although no SB ELSI project has yet been funded by ANR or CNRS. In the future, the inter-
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fields and other sciences (natural sciences, engineering, etc.). To deal with the interdiscipli-
nary nature of synthetic biology, the French funding organisations reacted by setting up 
multidisciplinary teams. In ANR, one third of the applications were interdisciplinary and 
reviewed by multiple scientific committees.
18
Switzerland
Switzerland is home to an active and productive research community in synthetic biology. 
Most projects have been funded by the Swiss National Science Foundation (SNSF). In 2007, 
SystemsX.ch was launched as the Swiss initiative in systems biology. It is a consortium com-
posed of eight universities and three research institutions. The Swiss government provides 
€66.7 million (CHF 100 million) for four years for SystemsX.ch, which has to be matched by 
another €66.7 million (CHF 100 million) by the SystemsX.ch partner institutions. Funding   
is mainly for interdisciplinary, inter-institutional projects.
19 Since issuing two calls for pro-
posals, 14 research-, technology- and development projects have been funded, allocating 
about 80% of the funding between 2008 and 2011.
20 Within the same measure, the Swiss 
government provides another €66.7 million (CHF 100 million) for the Department of 
Biosystems Science and Engineering (D-BSSE) in Basel, one of the most active SB research 
centres in Europe.
21 It was founded to bring together research from multiple disciplines of 
natural sciences, engineering, computing and mathematics, with synthetic biology being one 
of three research foci. Three synthetic biology-related projects were funded by SystemsX.ch. 
The total budget reserved for SB is approx. €5.33 million (CHF 8 million) per year for a 
4-year period from D-BSSE.
With a total annual budget of €480 million (CHF 719 million),
22 SNSF is the leading 
provider of scientific research funding for basic research in all disciplines, including applied 
research. Many synthetic biology-related projects have been funded by SNSF since 2002.
23 
Most of these projects have been supported by the funding for investigator-driven bottom-up 
research. All projects funded by SystemsX.ch and SNSF address the scientific aspects of 
synthetic biology, but not its societal and ELSI aspects. The projects supported by SNSF are 
more directed toward basic research, whereas SystemsX.ch supports both fundamental and 
applied research.
Aiming to improve cooperation with other European countries, SNSF has been a partner 
with the EU framework research programmes since 1987 and has participated in several ESF 
calls, including the call of EUROSYNBIO.
24
As an emerging field of research, synthetic biology is highly dependent upon innovations, 
many of which come from the interfaces of multiple scientific disciplines. Thus, expertise is 
required from a broad variety of disciplines. Although the interdisciplinary nature of synthetic 
biology might have posed problems for some funding organisations, this is not the case for 
SystemsX.ch. A typical research, technology and development project funded by SystemsX.ch 
is required to consist of researchers from at least two partner institutes.
25 In SNSF, interdisci-
plinary projects will be evaluated by the Specialised Committee for Interdisciplinary Research 
when the proposed projects include research topics from two or more disciplines.
26
Austria
Austria provided funding for several societal research projects despite the lack of national 
research and development (R&D) advances in synthetic biology. Among these research 
projects on social science, one project on biosafety issues of synthetic biology is funded by 
the Austrian Science Fund (FWF).
27 Two others on the science–society interface and percep-
tion of synthetic biology are funded by the Austrian Research Promotion Agency’s (FFG)
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GEN-AU ELSI programme.
29 In addition, the first European NEST project on safety and 
ethical aspects of synthetic biology was also initiated and coordinated by Austrian ELSI sci-
entists.
30
With a total annual funding of more than €100 million, FWF is the main funding body for 
basic science in Austria.
31 It supports all branches of science and the humanities. Within its 
funding categories for scientific disciplines, the FWF’s applied principle of competition is based 
solely on the quality of the proposal. No SB related basic research proposal has been submitted 
to the FWF so far, showing the lack of interest of the Austrian R&D community in SB.
FFG is the national funding agency for industrial research and development in Austria.
32 
The scientific officer of FFG expressed the opinion that synthetic biology is at the beginning 
stage and that SB-related research is more about basic research, explaining the lack of   
activities at FFG. Among FFG’s science programmes, however, is the Austrian Genome 
Research Programme (GEN-AU), which funds basic research projects and ELSI research.
33 
However, owing to the lack of active synthetic biology research, as well as to the lack of 
funding resulting from the current economic situation, no special call has been issued for 
synthetic biology. So far, no natural science research proposal dealing with synthetic biology 
has been submitted to FFG. Interestingly, the funded SB-related projects are concerned solely 
with societal aspects (ELSI) (Cserer and Seiringer, 2009; Ganguli-Mitra et al., 2009; Kelle, 
2009; Schmidt et al., 2009; Torgersen, 2009).
In Austria, R&D in synthetic biology is relatively sparse. Depending on how broadly 
synthetic biology is defined, we can identify a few research groups in Austria or none at all. 
Owing to the limited current SB research activities in Austria, the Austrian agencies consider 
funding at the national level to be sufficient for synthetic biology at present. Should Austrian 
scientists decide to start research in this field, funding resources do not seem to be a limiting 
factor.
As for future SB research proposals, the interdisciplinary nature of such projects is not 
seen as a problem for the Austrian funding agencies. The proposals submitted to FFG, for 
example, are required to be interdisciplinary in nature. As for FWF, the decision is made 
based solely on the quality of project applications, and the interdisciplinarity of a project is 
not seen as a hindrance.
The Netherlands
Several research funding organisations in the Netherlands may fund synthetic biology accord-
ing to their strategic focus. The most relevant ones are probably NWO, STW and the 
Netherlands Genomics Initiative (Hooshangi and Bentley, 2008). The Netherlands 
Organisation for Scientific Research (NWO), with an annual budget of €550 million, has a 
programme on systems biology that is closely related to and could theoretically serve as a 
starting point for synthetic biology research funding.
34 The Netherlands Genomics Initiative 
(Hooshangi and Bentley, 2008), established by the Dutch government in 2002, has a total 
budget of €280 million. It could also be a nucleus for future synthetic biology research fund-
ing.
35 Additionally, three Dutch universities allocated a total of €60 million to centres for 
synthetic biology research. The Delft University of Technology, with its department of nano-
science, invested €35 million over ten years. The University of Groningen, with the new 
Centre for Synthetic Biology, invested €10 million over five years. Finally, the Eindhoven 
University of Technology, with its institute for complex molecular systems, allocated €15 
million over ten years.
The major funding organisations more or less agree on their definition of synthetic 
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Synthetic biology is the engineering of biology: the synthesis of complex, biologically 
based (or inspired) systems which display functions that do not exist in nature.   
This engineering perspective may be applied at all levels of the hierarchy of biological 
structures – from individual molecules to whole cells, tissues and organisms. In essence, 
synthetic biology will enable the design of “biological systems” in a rational and systematic 
way. (EC, 2005)
One interviewee mentioned that he preferred a narrower definition of synthetic biology as 
“this will help to maintain the focus of the discipline within life science, leaving the ethical 
issues aside.”
Whereas NWO has not funded any projects in synthetic biology so far,
36 a representative 
from STW mentioned that “two sub-programmes of the nanotechnology research   
programme
37 of the Netherlands – NanoNed, the BioNanoSystems and the Chemistry and 
Physics of Individual Molecules – would provide a certain linkage.” However, no synthetic 
biology projects were funded within these programmes and no specific funding for synthetic 
biology has so far been available in the Netherlands. “One reason for this was that educating 
the public on synthetic biology needed to be done before specific funds can be set aside” 
explained one interviewee. “On the other hand,” argued one interviewee, “combining systems 
and synthetic biology would dilute the development in systems biology.”
As practical applications of synthetic biology are still out of reach, the interviewees agreed 
that “funding should be directed to fundamental research, although” one interviewee observed 
“a shift towards applied research can be seen at least in the nanotechnology-related subfield.”
Funding the investigation of societal aspects of emerging technologies has a long   
tradition in the Netherlands. NWO argued, however, that there are no specific funds within 
the life science section for ELSI analyses. Thus, the ELSI studies should be carried out via 
the societal section of NWO.
38 Multidisciplinarity is an issue for funding agencies in the 
Netherlands, and it seems easier to address this at the Dutch Technology Foundation STW, 
which forces groups to form multidisciplinary consortia. In contrast, NWO is more structured 
along the traditional disciplines, making it more complicated to address these issues.
Lack of private financial support in Europe
The European Commission has played an active role in fostering research in synthetic   
biology. In NEST a total of 18 SB research and policy projects were funded.
39 The total funding 
for these projects was over €32 million, of which one fourth was contributed by the   
participating countries (Table 1).
Considering the public funding for overall research and development as a percentage of 
national GDP, some European countries invested the same or even more than the US. Data 
from OECD indicated that, in 2005, the overall expenditure on R&D by EU27 was €168 bil-
lion versus €257 billion by the US.
40 Regarding publications in synthetic biology, up to 
November 2009, 31% of the publications (234 of 759) in the field were published by research-
ers in the European Union (EU27) versus 39% from US-based research groups (297 of 759) 
(Figure 1). The main difference between Europe and the US is the lack of commercial interest 
and investment in Europe. For example, the Bill and Melinda Gates Foundation recently 
donated €28 million ($42 million) to develop a synthetic form of artemisinin, an anti-malarial 
drug, in a collaboration between UC Berkeley and Amyris Biotechnologies.
41Amyris was also 
awarded €47 million ($70 million) to develop biofuel by a consortium of venture capitalists.
42 
Craig Venter’s Synthetic Genomics Inc. (SGI) signed a multi-year research and development   
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biofuels using photosynthetic algae. Total funding for SGI in research and development 
activities and milestone payments could amount to more than €200 million ($300 million).
43 
Similar investments in Europe have not been disclosed, and probably do not exist. We can 
speculate about the reasons for these different investment activities. The nature of synthetic 
biology research seems to be similar in the USA and Europe, at least when discussed among 
scientists at international conferences. Nonetheless, US scientists apparently manage more 
easily to move their research into the realm of near-commercial activities. In the view of 
company representatives, US research in synthetic biology seems to be more application driven   
compared to European research. This was at least the argument for BP to invest €333 million ($500 
million) in the Energy Bioscience Institute at UC Berkeley. According to a statement from BP, 
in the context of a European forum on synthetic biology organised by the European Commission 
in March 2010, they could not find an appropriate partner for their activities in Europe.
4. Conclusion
Our results show that the funding situation for synthetic biology varies considerably among 
European countries. Some countries have – in relation to their size – a considerable R&D 
community in SB, including the UK, France and Switzerland. In the Netherlands and 
Germany, the R&D community seems rather fragmented and less established than in the three 
aforementioned countries. Austria is the only country in our study that did not have an active 
R&D community under the label SB. The situation for SB ELSI research communities devi-
ates from R&D in several ways. A few scattered ELSI groups working on SB are located in 
France, Switzerland and the Netherlands. Germany is home to a small, nascent community of 
ELSI researchers in SB. Additionally, Germany is the only country where some ELSI aspects 
of SB, in particular security issues for DNA synthesis, are driven by the private sector, namely 
the German DNA synthesis companies themselves. Austria, although lacking an R&D   
Table 3. Funding landscape for synthetic biology and its ELSI research in six European countries
Country
Synthetic biology (SB) ELSI of SB
Link funding–community Community Funding Community Funding
Austria not existing potentially  
available
existing available SB: lack of Austrian SB 
community although 
funding would be 
available, ELSI: good
France existing hardly  
available
emerging not available general lack of funding
Germany  emerging potentially  
available
existing available community and funding 
hardly synchronised, more 
money available than spent
Netherlands emerging available emerging hardly  
available
SB: good, ELSI: funding 
difficulties
Switzerland existing available emerging not available SB: good, ELSI: funding 
difficulties
UK existing available existing available overall good situation, 
community and funding 
available and synchronised160    Public Understanding of Science 21 (2) 
community, has several ELSI groups working on different aspects of SB, funded through 
European and national sources. The UK, in contrast, is the only country with an established 
funding scheme for R&D and ELSI (which, however, is sometimes impaired by the detached 
structure of the individual research councils). See Table 3 for details.
The best funding situation for R&D and ELSI in SB can probably be found in the UK. 
France, although having an active R&D community, apparently provides insufficient funding 
for them, and even less for the ELSI community. Switzerland has a good funding situation for 
its active R&D community, but less so for its ELSI community. The Netherlands does provide 
some funding for its R&D community, but less so for its ELSI scientists in SB. While Austria 
has enough funding for synthetic biology research, no researchers have yet applied for these 
funds, and the only researchers receiving funding are working on societal aspects. In Germany, 
public funding agencies and the research community (both R&D and ELSI) appear to be   
sub-optimally linked together. While several R&D groups work on SB, the funding agencies 
commented that hardly any proposal is submitted to them through the bottom-up approach.
Most of the funding for synthetic biology in Europe is contributed by public sources. We 
can speculate that the increasing commercial prospects of synthetic biology will attract addi-
tional public funding for the technology-driven economy as well as funding from the private 
sector, which is still not the case in Europe.
The development of synthetic biology promises to provide a better understanding to 
answer basic questions about life. It also holds promise for useful applications, such as new 
energy, new biomaterials, and new medicines. All these involve different societal ramifica-
tions. This calls for conducting research on such societal ramifications and on ethical, legal 
and social issues (ELSI). Owing to the nature of synthetic biology, research on ELSI can 
hardly fit into any single discipline. Therefore, such work should also be conducted with an 
interdisciplinary perspective to build up new links between natural sciences and the social 
sciences and humanities (Rabinow and Bennett, 2009). With the exception of the UK, how-
ever, which is attempting to foster this interaction through its funding scheme (and a few 
cases on the provincial level in Germany), this interaction is mostly missing in Europe. The 
reasons for this lack of integration are country specific, reflecting for example a lack of an 
established ELSI community in SB (France, Switzerland, Netherlands), lack of funding 
opportunities (France), lack of an R&D community (Austria), or poor linkage of the available 
groups with established funding opportunities (Germany).
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Notes
 1    See: EC, 2005 at www.synbiosafe.eu/uploads///pdf/EU-highlevel-syntheticbiology.pdf and EC, 2007 at http://
cordis.europa.eu/nest/
  2  See: www.gopubmed.orgPei et al.: Synthetic biology and European funding    161
 3    See http://www.esf.org/activities/eurocores/programmes/eurosynthetic biology/funding-agencies-and-contacts.
html for list of countries that support the EUROCORES EUROSYNTHETIC BIOLOGY call.
 4  http://www.bmbf.de/en/1056.php
  5    See press release from 6 November 2009: http://idw-online.de/pages/de/news342927 and http://www.uni-mar-
burg.de/aktuelles/news/2009a/0708b
 6  http://www.bmbf.de/en/1237.php
 7  http://www.bbsrc.ac.uk/publications/corporate/synthetic_biology.pdf
 8  http://www.epsrc.ac.uk/AboutEPSRC/Plans/M3E.htm
 9    See: “Synthetic Biology Sandpit: Collaboration Between EPSRC and US NSF” at http://www.epsrc.ac.uk/
newsevents/news/2009/Pages/syntheticbiologysandpit.aspx
10    The UK Royal Society, together with the OECD and the US National Academies of Sciences co-organised a 
joint International Symposium on Opportunities and Challenges in the Emerging Field of Synthetic Biology in 
July 2009 in Washington, DC. See: http://sites.nationalacademies.org/PGA/stl/PGA_050738
11    In October 2009 the Wellcome Trust – the UK’s largest medical research charity – announced that it is offering 
teams of students stipends to enable them to enter the International Genetically Engineered Machine competi-
tion (iGEM) 2010. The stipend will provide promising undergraduates with hands-on experience in synthetic 
biology. See: http://www.wellcome.ac.uk/News/Media-office/Press-releases/2009/WTX056649.htm
12   http://www.sgm.ac.uk/news/consultations/sgmcon082.pdf
13    The review, by Andrew Balmer and Paul Martin, can be downloaded from http://www.synthetic biologyethics.org
14   http://www.agence-nationale-recherche.fr/AAPProjetsOuverts?lngAAPId=198
15   http://www.cnrs.fr/en/aboutCNRS/key-figures.htm
16    EPST: Etablissements publics à caractère scientifique et technologique (French public institutions for science 
and technology).
17 http://www.agence-nationale-recherche.fr/documents/uploaded/2008/ANR-Annual-Report-2007.pdf
18 http://www.agence-nationale-recherche.fr/documents/uploaded/2008/ANR-Annual-Report-2007.pdf
19 http://www.systemsx.ch/about-us/what-is-systemsxch/
20 http://www.systemsx.ch/projects/systemsxch-projekte/rtd-projekte/?L=3
21  See: http://www.bsse.ethz.ch/
22 http://www.snf.ch/E/aboutus/facts/Pages/statistics.aspx
23 http://www.projectdb.snf.ch/WebForms/Frameset.aspx
24 http://www.snf.ch/E/international/Pages/default.aspx
25 http://www.systemsx.ch/about-us/what-is-systemsxch
26 http://www.snf.ch/E/current/Dossiers/Pages/interdisciplinary.aspx
27 http://www.idialog.eu/fwf
28 http://www.synbio.at
29 http://www.cisynbio.com
30 http://www.synbiosafe.eu
31 http://www.fwf.ac.at/en/index.asp
32 http://www.ffg.at/content.php?version=2
33 http://www.gen-au.at/artikel.jsp?id=781&type=news&lang=de
34    Health Council of the Netherlands, Advisory Council on Health Research, and Royal Netherlands Academy of 
Arts and Sciences. “Synthetic Biology: Creating Opportunities.” The Hague: Health Council of the Netherlands, 
2008; publication no. 2008/19E. ISBN 978-90-5549-742-3.
35    See note 34, page 1.
36  However, support for Dutch individual projects within the ESF EUROSYNBIO call was ensured.
37    Among others, NanoNed aims at strengthening Dutch knowledge infrastructure through a comprehensive 
knowledge transfer approach, leading to industrial nanotechnology applications (processes, products, services, 
general industrial activities). Additionally, NanoNed devotes attention to societal output and the innovation 
process (source: http://www.nanoned.nl/valorisation.html).
38    Although not dealing with synthetic biology, the NGI-related Dutch Centre for Society and Genomics (CSG) 
analyses, assesses and improves the relationship between society and genomics research. The CSG might   
serve as a starting point for future projects dealing with ELSI of synthetic biology. See: http://www.society-
genomics.nl
39 ftp://ftp.cordis.europa.eu/pub/nest/docs/5-nest-synthetic-080507.pdf
40 http://stats.oecd.org/Index.aspx?DatasetCode=CSP2009
41 http://berkeley.edu/news/media/releases/2004/12/13_gates.shtml
42 http://www.amyrisbiotech.com/index.php?option=com_content&task=view&id=50&Itemid=307
43 http://www.syntheticgenomics.com/media/press/71409.html162    Public Understanding of Science 21 (2) 
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